| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 54
| Issue : 1 | Page : 7-10 |
|
|
Postablation and α-1 blocker therapy in children with congenital obstructing posterior urethral membrane
Minu Bajpai1, Aejaz Baba1, Amit Kumar Singh2
1 Department of Pediatric Surgery AIIMS, New Delhi, India
2 Department of Trauma, Apex Trauma Centre Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Correspondence Address:
Amit Kumar Singh
Department of Trauma Surgery, Apex Trauma Centre, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow - 226 014, Uttar Pradesh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/fjs.fjs_97_20
|
|
|
Background: Congenital obstructing posterior urethral membrane (COPUM) or posterior urethral valve (PUV) is the most common cause of lower urinary tract obstruction in boys. Approximately one-third of boys with PUV develop end-stage renal disease. Various prognostic factors have been recognized which determines the long-term outcome of these cases.
Materials and Methods: This was a retrospective case–control analysis of data from January 1998 to May 2014. All patients of COPUM with radiological evidence of bladder neck hypertrophy with follow-up of 7 years were included in the study. Patients with urethral strictures, neurogenic bladder, and incomplete records were excluded. Group I (n = 57) received selective α-1 blocker (prazosin), after valve ablation. Group II (n = 36) who had not received the α-1 blocker was treated as a control group. Investigations include renal function test, ultrasonography, micturating cystourethrography renal dynamic scan, and glomerular filtration rate. Statistical analysis was done using the paired t-test, multiple serial analyses using ANOVA. P <0.05 was considered as significant.
Results: A total of 113 patients of COPUM were treated from January 1998 to May 2014. Out of these 113, 93 patients (82.3%) were included in the study. Fifty-seven (61.2%) received α-1 blocker, while 36 patients (38.8%) acted as control. Significant decrease in bladder neck hypertrophy noted in Group I as compared to Group II (P<0.001).
Conclusion: Uses of alpha-1 blocker hastens the recovery in terms of clinical improvement, resolution of bladder neck hypertrophy, and improved peak urine flow rate.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
